Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV.

Cancer Cell. 2019 Oct 14;36(4):444-457.e7. doi: 10.1016/j.ccell.2019.09.001. Epub 2019 Oct 3.

PMID:
31588020
2.

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer.

Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas V, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.

Clin Cancer Res. 2019 Sep 23. pii: clincanres.1667.2019. doi: 10.1158/1078-0432.CCR-19-1667. [Epub ahead of print]

PMID:
31548343
3.

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.

Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI.

Clin Cancer Res. 2019 Aug 4. doi: 10.1158/1078-0432.CCR-19-1324. [Epub ahead of print]

PMID:
31383735
4.

Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.

Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R.

Mol Cancer Ther. 2019 Oct;18(10):1852-1862. doi: 10.1158/1535-7163.MCT-18-0965. Epub 2019 Jul 18.

PMID:
31320401
5.

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.

Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D.

Clin Cancer Res. 2019 Oct 15;25(20):6119-6126. doi: 10.1158/1078-0432.CCR-19-0879. Epub 2019 Jul 12.

PMID:
31300452
6.

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.

Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi O.

Clin Cancer Res. 2019 Oct 1;25(19):5832-5842. doi: 10.1158/1078-0432.CCR-18-4049. Epub 2019 Jul 12.

7.

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies.

Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00180. Epub 2019 Jan 22.

8.

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival.

Kato S, Schwaederlé MC, Fanta PT, Okamura R, Leichman L, Lippman SM, Lanman RB, Raymond VM, Talasaz A, Kurzrock R.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00158. Epub 2019 Jan 25.

9.

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort.

Lee J, Franovic A, Shiotsu Y, Kim ST, Kim KM, Banks KC, Raymond VM, Lanman RB.

Front Oncol. 2019 Apr 4;9:212. doi: 10.3389/fonc.2019.00212. eCollection 2019.

10.

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.

Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA.

Clin Cancer Res. 2019 Aug 1;25(15):4691-4700. doi: 10.1158/1078-0432.CCR-19-0624. Epub 2019 Apr 15.

PMID:
30988079
11.

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors.

Piccioni DE, Achrol AS, Kiedrowski LA, Banks KC, Boucher N, Barkhoudarian G, Kelly DF, Juarez T, Lanman RB, Raymond VM, Nguyen M, Truong JD, Heng A, Gill J, Saria M, Pingle SC, Kesari S.

CNS Oncol. 2019 Jun;8(2):CNS34. doi: 10.2217/cns-2018-0015. Epub 2019 Mar 11.

12.

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S.

Ann Oncol. 2019 Feb 1;30(2):243-249. doi: 10.1093/annonc/mdy509.

PMID:
30462160
13.

Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.

Baumgartner JM, Raymond VM, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R.

Ann Surg Oncol. 2018 Aug;25(8):2400-2408. doi: 10.1245/s10434-018-6561-z. Epub 2018 Jun 14.

14.

Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.

Loong HH, Raymond VM, Shiotsu Y, Chua DTT, Teo PML, Yung T, Skrzypczak S, Lanman RB, Mok TSK.

Clin Lung Cancer. 2018 Sep;19(5):e601-e608. doi: 10.1016/j.cllc.2018.04.022. Epub 2018 May 7.

PMID:
29807856
15.

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.

McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC.

Clin Cancer Res. 2018 Jun 15;24(12):2758-2770. doi: 10.1158/1078-0432.CCR-17-2588. Epub 2018 Mar 29.

16.

Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.

Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS.

Oncotarget. 2017 Oct 26;8(58):97769-97786. doi: 10.18632/oncotarget.22080. eCollection 2017 Nov 17.

17.

Urine test for EGFR analysis in patients with non-small cell lung cancer.

Franovic A, Raymond VM, Erlander MG, Reckamp KL.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1323-S1331. doi: 10.21037/jtd.2017.06.144. Review.

18.

Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.

Dizman N, Bergerot P, Bergerot C, Lanman RB, Raymond VM, Banks KC, Jones J, Pal SK.

Eur Urol. 2018 Feb;73(2):308-310. doi: 10.1016/j.eururo.2017.08.006. Epub 2017 Aug 24. No abstract available.

PMID:
28844598
19.

Physician Experiences and Understanding of Genomic Sequencing in Oncology.

Weipert CM, Ryan KA, Everett JN, Yashar BM, Chinnaiyan AM, Scott Roberts J, De Vries R, Zikmund-Fisher BJ, Raymond VM.

J Genet Couns. 2018 Feb;27(1):187-196. doi: 10.1007/s10897-017-0134-3. Epub 2017 Aug 24.

20.

Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.

Tchekmedyian N, Mudad R, Blanco FF, Raymond VM, Garst J, Erlander MG, Haura E, Berz D.

Lung Cancer. 2017 Jun;108:22-28. doi: 10.1016/j.lungcan.2017.02.010. Epub 2017 Feb 20.

PMID:
28625639
21.

Development of a Streamlined Work Flow for Handling Patients' Genetic Testing Insurance Authorizations.

Uhlmann WR, Schwalm K, Raymond VM.

J Genet Couns. 2017 Aug;26(4):657-668. doi: 10.1007/s10897-017-0098-3. Epub 2017 Apr 24.

22.

Large, Prospective Analysis of the Reasons Patients Do Not Pursue BRCA Genetic Testing Following Genetic Counseling.

Hayden S, Mange S, Duquette D, Petrucelli N, Raymond VM; BRCA Clinical Network Partners.

J Genet Couns. 2017 Aug;26(4):859-865. doi: 10.1007/s10897-016-0064-5. Epub 2017 Jan 16.

23.

Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories.

Raymond VM, Gray SW, Roychowdhury S, Joffe S, Chinnaiyan AM, Parsons DW, Plon SE; Clinical Sequencing Exploratory Research Consortium Tumor Working Group.

J Natl Cancer Inst. 2015 Nov 20;108(4). pii: djv351. doi: 10.1093/jnci/djv351. Print 2016 Apr.

24.

Illustrative case studies in the return of exome and genome sequencing results.

Amendola LM, Lautenbach D, Scollon S, Bernhardt B, Biswas S, East K, Everett J, Gilmore MJ, Himes P, Raymond VM, Wynn J, Hart R; CSER Genetic Counseling Working Group, Jarvik GP.

Per Med. 2015;12(3):283-295.

25.

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.

Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, Ning Y, Su F, Wang R, Stoffel EM, Innis JW, Roberts JS, Robertson PL, Yanik G, Chamdin A, Connelly JA, Choi S, Harris AC, Kitko C, Rao RJ, Levine JE, Castle VP, Hutchinson RJ, Talpaz M, Robinson DR, Chinnaiyan AM.

JAMA. 2015 Sep 1;314(9):913-25. doi: 10.1001/jama.2015.10080.

26.

Genetic and environmental risk assessment and colorectal cancer screening.

Pirzadeh-Miller SM, Raymond VM, Knapke S.

Ann Intern Med. 2015 Apr 7;162(7):526. doi: 10.7326/L15-5072. No abstract available.

PMID:
25845003
27.

Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer.

Berz D, Raymond VM, Garst JH, Erlander MG.

Exp Hematol Oncol. 2016 Aug 8;5:24. doi: 10.1186/s40164-016-0052-3. eCollection 2015.

28.

Outcomes of genetic evaluation for hereditary cancer syndromes in unaffected individuals.

Gustafson SL, Raymond VM, Marvin ML, Else T, Koeppe E, Stoffel EM, Everett JN.

Fam Cancer. 2015 Mar;14(1):167-74. doi: 10.1007/s10689-014-9756-x.

PMID:
25245322
29.

MLH1 promotor hypermethylation does not rule out a diagnosis of Lynch syndrome: a case report.

Raymond VM, Morris AM, Hafez KS, Greenson JK.

Fam Cancer. 2015 Mar;14(1):77-80. doi: 10.1007/s10689-014-9753-0.

PMID:
25213678
30.

Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.

Everett JN, Raymond VM, Dandapani M, Marvin M, Kohlmann W, Chittenden A, Koeppe E, Gustafson SL, Else T, Fullen DR, Johnson TM, Syngal S, Gruber SB, Stoffel EM.

JAMA Dermatol. 2014 Dec;150(12):1315-21.

31.

The clinical phenotype of SDHC-associated hereditary paraganglioma syndrome (PGL3).

Else T, Marvin ML, Everett JN, Gruber SB, Arts HA, Stoffel EM, Auchus RJ, Raymond VM.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1482-6. doi: 10.1210/jc.2013-3853. Epub 2014 Apr 23.

32.

Traditional roles in a non-traditional setting: genetic counseling in precision oncology.

Everett JN, Gustafson SL, Raymond VM.

J Genet Couns. 2014 Aug;23(4):655-60. doi: 10.1007/s10897-014-9698-3. Epub 2014 Mar 1.

33.

Adrenocortical carcinoma.

Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD.

Endocr Rev. 2014 Apr;35(2):282-326. doi: 10.1210/er.2013-1029. Epub 2013 Dec 20. Review.

34.

An oncocytic adrenal tumour in a patient with Birt-Hogg-Dubé syndrome.

Raymond VM, Long JM, Everett JN, Caoili EM, Gruber SB, Stoffel EM, Giordano TJ, Hammer GD, Else T.

Clin Endocrinol (Oxf). 2014 Jun;80(6):925-7. doi: 10.1111/cen.12292. Epub 2013 Aug 5. No abstract available.

35.

Adrenocortical carcinoma is a lynch syndrome-associated cancer.

Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, Hammer GD, Stoffel EM, Greenson JK, Giordano TJ, Else T.

J Clin Oncol. 2013 Aug 20;31(24):3012-8. doi: 10.1200/JCO.2012.48.0988. Epub 2013 Jul 22. Erratum in: J Clin Oncol. 2013 Oct 1;31(28):3612.

36.

Familial gastric and pancreatic cancers: Diagnosis and screening.

Raymond VM, Stoffel EM.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e44. Review.

37.

Elevated risk of prostate cancer among men with Lynch syndrome.

Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, Syngal S, Cooney KA, Gruber SB.

J Clin Oncol. 2013 May 10;31(14):1713-8. doi: 10.1200/JCO.2012.44.1238. Epub 2013 Mar 25.

38.

Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma.

Raymond VM, Else T, Everett JN, Long JM, Gruber SB, Hammer GD.

J Clin Endocrinol Metab. 2013 Jan;98(1):E119-25. doi: 10.1210/jc.2012-2198. Epub 2012 Nov 21.

39.

Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome.

Raymond VM, Herron CM, Giordano TJ, Gruber SB.

Fam Cancer. 2012 Mar;11(1):115-21. doi: 10.1007/s10689-011-9485-3.

PMID:
22127509
40.

An American founder mutation in MLH1.

Tomsic J, Liyanarachchi S, Hampel H, Morak M, Thomas BC, Raymond VM, Chittenden A, Schackert HK, Gruber SB, Syngal S, Viel A, Holinski-Feder E, Thibodeau SN, de la Chapelle A.

Int J Cancer. 2012 May 1;130(9):2088-95. doi: 10.1002/ijc.26233. Epub 2011 Aug 30.

41.

A review of statistical methods for testing genetic anticipation: looking for an answer in Lynch syndrome.

Boonstra PS, Gruber SB, Raymond VM, Huang SC, Timshel S, Nilbert M, Mukherjee B.

Genet Epidemiol. 2010 Nov;34(7):756-68. doi: 10.1002/gepi.20534. Review.

42.

Hereditary prostate cancer as a feature of Lynch syndrome.

Bauer CM, Ray AM, Halstead-Nussloch BA, Dekker RG, Raymond VM, Gruber SB, Cooney KA.

Fam Cancer. 2011 Mar;10(1):37-42. doi: 10.1007/s10689-010-9388-8.

43.

Allele-specific expression of APC in adenomatous polyposis families.

Castellsagué E, González S, Guinó E, Stevens KN, Borràs E, Raymond VM, Lázaro C, Blanco I, Gruber SB, Capellá G.

Gastroenterology. 2010 Aug;139(2):439-47, 447.e1. doi: 10.1053/j.gastro.2010.04.047. Epub 2010 Apr 29.

44.

Risk of pancreatic cancer in families with Lynch syndrome.

Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB, Syngal S.

JAMA. 2009 Oct 28;302(16):1790-5. doi: 10.1001/jama.2009.1529.

45.

Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.

Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S, Gruber SB.

Gastroenterology. 2009 Nov;137(5):1621-7. doi: 10.1053/j.gastro.2009.07.039. Epub 2009 Jul 18.

46.

Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis.

Rothberg AE, Raymond VM, Gruber SB, Sisson J.

Thyroid. 2009 Jun;19(6):651-5. doi: 10.1089/thy.2009.0021.

47.

Genetic counselling and genetic testing in hereditary gastrointestinal cancer syndromes.

Raymond VM, Everett JN.

Best Pract Res Clin Gastroenterol. 2009;23(2):275-83. doi: 10.1016/j.bpg.2009.02.009. Review.

PMID:
19414152
48.

Pediatric duodenal cancer and biallelic mismatch repair gene mutations.

Roy S, Raskin L, Raymond VM, Thibodeau SN, Mody RJ, Gruber SB.

Pediatr Blood Cancer. 2009 Jul;53(1):116-20. doi: 10.1002/pbc.21957.

49.

First description of parathyroid disease in multiple endocrine neoplasia 2A syndrome.

Sisson JC, Giordano TJ, Raymond VM, Doherty GM, Gruber SB.

Endocr Pathol. 2008 Winter;19(4):289-93. doi: 10.1007/s12022-008-9049-8.

Supplemental Content

Loading ...
Support Center